Cardio Diagnostics Holdings, Inc.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.8K
- Net income
- -$6.5M
- Total assets
- $7.8M
- Market cap
- $5.8M
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $5.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 26, 2022
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Cardio Diagnostics Holdings, Inc..
